amantadine has been researched along with Drug Withdrawal Symptoms in 38 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "We present three patients who, after long-term therapy with amantadine (4 to 18 years), experienced an acute delirium with confusion, disorientation, agitation, and paranoia on withdrawal." | 7.70 | Acute delirium after withdrawal of amantadine in Parkinson's disease. ( Brown, DL; Factor, SA; Molho, ES, 1998) |
| "Nineteen patients with senile brain disease (including 2 with parkinsonian symptoms) were treated with amantadine in an oral dosage of 200--300 mg daily." | 5.26 | Amantadine in senile dementia: electroencephalographic and clinical effects. ( Boillat, J; Cole, M; Dastoor, DP; Klingner, A; Müller, HF, 1979) |
| "We report a case of a man with spinocerebellar ataxia (SCA) on high-dose amantadine who was admitted for acute on chronic dysphagia secondary to progression of SCA." | 4.31 | Amantadine withdrawal in a patient with spinocerebellar ataxia. ( Chang, E; Pak, A, 2023) |
| " Under conditions of morphine withdrawal, intraperitoneal injection of amantadine (10 or 20 mg/kg) decreased motor activity and promoted body weight loss in parallel with the development of mechanical allodynia, but had no effect on the total withdrawal score." | 3.91 | Comparative Assessment of the Effectiveness of Noncompetitive NMDA Receptor Antagonists Amantadine and Hemantane in Morphine Withdrawal Syndrome Model. ( Kolik, LG; Konstantinopolsky, MA, 2019) |
| "Amantadine, which was originally developed as an antiviral medication, functions as a dopamine agonist in the central nervous system and consequently is utilized in the treatment of Parkinson disease, drug-induced extrapyramidal reactions, and neuroleptic malignant syndrome." | 3.85 | The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status. ( Fox, J; Fryml, LD; Pelic, CG; Revuelta, GJ; Robert, S; Sahlem, G; Short, EB; Williams, KR, 2017) |
| "We present three patients who, after long-term therapy with amantadine (4 to 18 years), experienced an acute delirium with confusion, disorientation, agitation, and paranoia on withdrawal." | 3.70 | Acute delirium after withdrawal of amantadine in Parkinson's disease. ( Brown, DL; Factor, SA; Molho, ES, 1998) |
| "amantadine was withdrawn in all patients." | 2.70 | Amantadine for dyskinesia in patients affected by severe Parkinson's disease. ( Onofrj, M; Paci, C; Thomas, A, 2001) |
| "Among subjects with severe cocaine withdrawal symptoms at the start of treatment, those who received amantadine used significantly less cocaine during the trial than did subjects who received placebo." | 2.69 | Amantadine in the treatment of cocaine-dependent patients with severe withdrawal symptoms. ( Alterman, AI; Cornish, J; Kampman, KM; O'Brien, CP; Volpicelli, JR, 2000) |
| "Amantadine was well tolerated." | 2.68 | Amantadine does not reduce cocaine use or craving in cocaine-dependent methadone maintenance patients. ( Handelsman, L; Limpitlaw, L; Paris, P; Schmeidler, J; Stimmel, B; Williams, D, 1995) |
| "Bromocriptine was significantly more effective than both throughout the latter phase of the study." | 2.66 | Bromocriptine and amantadine in cocaine detoxification. ( Feather, JN; Folts, DJ; Giannini, AJ; Sullivan, BS, 1989) |
| "Buprenorphine was superior to clonidine in controlling severe withdrawal symptoms in an outpatient setting (RR 0." | 2.58 | Pharmacological therapies for management of opium withdrawal. ( Amato, L; Amin-Esmaeili, M; Gholami, J; Hoseinie, L; Rahimi-Movaghar, A; Yousefi-Nooraie, R, 2018) |
| "Nineteen patients with senile brain disease (including 2 with parkinsonian symptoms) were treated with amantadine in an oral dosage of 200--300 mg daily." | 1.26 | Amantadine in senile dementia: electroencephalographic and clinical effects. ( Boillat, J; Cole, M; Dastoor, DP; Klingner, A; Müller, HF, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (42.11) | 18.7374 |
| 1990's | 9 (23.68) | 18.2507 |
| 2000's | 7 (18.42) | 29.6817 |
| 2010's | 4 (10.53) | 24.3611 |
| 2020's | 2 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Pak, A | 1 |
| Chang, E | 1 |
| Koschel, J | 1 |
| Ray Chaudhuri, K | 1 |
| Tönges, L | 1 |
| Thiel, M | 1 |
| Raeder, V | 1 |
| Jost, WH | 1 |
| Fryml, LD | 1 |
| Williams, KR | 1 |
| Pelic, CG | 1 |
| Fox, J | 1 |
| Sahlem, G | 1 |
| Robert, S | 1 |
| Revuelta, GJ | 1 |
| Short, EB | 1 |
| Rahimi-Movaghar, A | 1 |
| Gholami, J | 1 |
| Amato, L | 1 |
| Hoseinie, L | 1 |
| Yousefi-Nooraie, R | 1 |
| Amin-Esmaeili, M | 1 |
| Kolik, LG | 1 |
| Konstantinopolsky, MA | 1 |
| Brantley, E | 1 |
| Cohn, J | 1 |
| Babu, K | 1 |
| Cheung, YF | 1 |
| Hui, CH | 1 |
| Chan, JH | 1 |
| Kampman, KM | 2 |
| Dackis, C | 1 |
| Lynch, KG | 1 |
| Pettinati, H | 1 |
| Tirado, C | 1 |
| Gariti, P | 1 |
| Sparkman, T | 1 |
| Atzram, M | 1 |
| O'Brien, CP | 3 |
| Shinohara, Y | 1 |
| Hayakawa, N | 1 |
| Alphs, L | 1 |
| Davis, JM | 1 |
| Simpson, DM | 1 |
| Davis, GC | 1 |
| Bower, DJ | 1 |
| Chalasani, P | 1 |
| Ammons, JC | 1 |
| King, GR | 1 |
| Joyner, C | 1 |
| Ellinwood, EH | 1 |
| Weller, M | 1 |
| Kornhuber, J | 1 |
| Handelsman, L | 1 |
| Limpitlaw, L | 1 |
| Williams, D | 1 |
| Schmeidler, J | 1 |
| Paris, P | 1 |
| Stimmel, B | 1 |
| Factor, SA | 1 |
| Molho, ES | 1 |
| Brown, DL | 1 |
| Miyasaki, JM | 1 |
| Grimes, D | 1 |
| Lang, AE | 1 |
| Volpicelli, JR | 1 |
| Alterman, AI | 2 |
| Cornish, J | 1 |
| Pérez de los Cobos, J | 1 |
| Duro, P | 1 |
| Trujols, J | 1 |
| Tejero, A | 1 |
| Batlle, F | 1 |
| Ribalta, E | 1 |
| Casas, M | 1 |
| Ito, T | 1 |
| Shibata, K | 1 |
| Watanabe, A | 1 |
| Akabane, J | 1 |
| Paci, C | 1 |
| Thomas, A | 1 |
| Onofrj, M | 1 |
| Way, EL | 1 |
| Iwamoto, ET | 1 |
| Khanna, S | 1 |
| Ho, IK | 1 |
| Shen, F | 1 |
| Loh, HH | 1 |
| Timberlake, WH | 1 |
| Vance, MA | 1 |
| Müller, HF | 1 |
| Dastoor, DP | 1 |
| Klingner, A | 1 |
| Cole, M | 1 |
| Boillat, J | 1 |
| Kolar, AF | 1 |
| Brown, BS | 1 |
| Weddington, WW | 1 |
| Haertzen, CC | 1 |
| Michaelson, BS | 1 |
| Jaffe, JH | 1 |
| Droba, M | 1 |
| Antelo, RE | 1 |
| Cornish, JW | 1 |
| Sweeney, KK | 1 |
| Parikh, GA | 1 |
| Kaliszuk, S | 1 |
| Borzecki, Z | 1 |
| Swies, Z | 1 |
| Giannini, AJ | 1 |
| Folts, DJ | 1 |
| Feather, JN | 1 |
| Sullivan, BS | 1 |
| Hermesh, H | 1 |
| Sirota, P | 1 |
| Eviatar, J | 1 |
| Pike, RF | 1 |
| Morgan, C | 1 |
| Kosten, T | 1 |
| Gawin, F | 1 |
| Kleber, H | 1 |
| Tennant, F | 1 |
| Berman, ML | 1 |
| Kumar, V | 1 |
| Tennant, FS | 1 |
| Sagherian, AA | 1 |
| Lazarus, A | 1 |
| Rosse, R | 1 |
| Ciolino, C | 1 |
| Fehling, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Placebo Controlled Trial of Propranolol and Amantadine for the Treatment of Cocaine Dependent Subjects With Severe Cocaine Withdrawal Symptoms[NCT00158132] | Phase 2 | 199 participants (Actual) | Interventional | 1999-09-30 | Completed | ||
| Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)[NCT02202551] | Phase 3 | 223 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"To evaluate clinical progression of PD as assessed by the MDS-UPDRS, combined score, Parts I, II, and III.~Part I - non-motor experiences of daily living; Part II - motor experiences of daily living; Part III - motor examination. Parts I and II each contain 13 questions measured on a 5-point scale (0-4). Part III contains 18 objective rater assessments of the motor signs of PD measured on a 5-point scale (0-4).~Total range for combined score (Part I-III) is = 0-176. Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better.~Parts I, II, and III are summed to make the total score." (NCT02202551)
Timeframe: Up to 101 weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change from Baseline at Week 8 | Change from Baseline at Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| ADS-5102 1A | 41.8 | 1.2 | 1.6 | 4.8 | 7.5 | 13.2 | 8.8 | 11.7 | 11.3 | 11.4 |
| ADS-5102 Group 1P | 45.6 | -2.8 | -1.4 | 1.5 | -0.4 | 2.6 | 2.6 | 7.3 | 3.7 | 3.7 |
| ADS-5102 Group 2 | 52.8 | 0.8 | 5.7 | 6.5 | 1.6 | 6.1 | 6.1 | 9.4 | 6.4 | 6.5 |
| ADS-5102 Group 3 | 52.4 | -5.3 | -5.2 | -5.3 | -4.8 | -4.6 | -4.6 | -4.9 | 0.9 | 4.1 |
"This component (Questions 4.1 - 4.6) includes time spent with dyskinesia, functional impact of dyskinesia, time spent in OFF state, functional impact of fluctuations, complexity of motor fluctuations, painful OFF-state dystonia. Questions 4.1-4.6 are summed to make the Part IV score.~Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better. Total range for Part IV is = 0-24" (NCT02202551)
Timeframe: 100 Weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change in Baseline from Week 8 | Change in Baseline from Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| Group 1a | 6.5 | -0.2 | -0.8 | -0.3 | 0.0 | 0.2 | 0.4 | 0.9 | 0.4 | 0.4 |
| Group 1P | 9.6 | -3.4 | -3.2 | -3.3 | -2.8 | -2.9 | -3.3 | -2.9 | -2.8 | -2.4 |
| Group 2 | 9.8 | -3.6 | -1.1 | -1.4 | -2.9 | -2.5 | -1.9 | -2.7 | -3.7 | -3.6 |
| Group 3 | 10.4 | -4.0 | -3.9 | -4.4 | -4.7 | -3.6 | -2.5 | -3.7 | -4.3 | -3.6 |
The primary objective of the study was to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release (ER) formulation of amantadine, administered at a dose of 340 mg once daily at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). (NCT02202551)
Timeframe: Up to 101 weeks
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AE | Study drug-related AE | SAEs | Permanent discontinuation due to AE | Permanent discontinuation due to drug-related AE | Mild AEs | Moderate AEs | Mild drug-related AE | Moderate drug-related AE | Severe drug-related AE | |
| Group 1a | 57 | 31 | 16 | 12 | 4 | 12 | 25 | 16 | 12 | 3 |
| Group 1P | 70 | 45 | 21 | 21 | 15 | 13 | 36 | 15 | 23 | 7 |
| Group 2 | 23 | 16 | 6 | 6 | 4 | 3 | 13 | 3 | 12 | 1 |
| Group 3 | 55 | 32 | 17 | 10 | 8 | 11 | 26 | 5 | 22 | 5 |
2 reviews available for amantadine and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Implications of dopaminergic medication withdrawal in Parkinson's disease.
Topics: Amantadine; Dopamine; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Substance Withdrawal S | 2022 |
Pharmacological therapies for management of opium withdrawal.
Topics: Amantadine; Amines; Baclofen; Buprenorphine; Clonidine; Cyclohexanecarboxylic Acids; Gabapentin; gam | 2018 |
12 trials available for amantadine and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms.
Topics: Adrenergic beta-Antagonists; Adult; Amantadine; Analgesics, Non-Narcotic; Cocaine; Cocaine-Related D | 2006 |
Amantadine does not reduce cocaine use or craving in cocaine-dependent methadone maintenance patients.
Topics: Adult; Amantadine; Cocaine; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method | 1995 |
Amantadine in the treatment of cocaine-dependent patients with severe withdrawal symptoms.
Topics: Amantadine; Ambulatory Care; Cocaine; Cocaine-Related Disorders; Dopamine Agents; Double-Blind Metho | 2000 |
Methadone tapering plus amantadine to detoxify heroin-dependent inpatients with or without an active cocaine use disorder: two randomised controlled trials.
Topics: Adolescent; Adult; Amantadine; Cocaine-Related Disorders; Comorbidity; Dose-Response Relationship, D | 2001 |
Amantadine for dyskinesia in patients affected by severe Parkinson's disease.
Topics: Aged; Amantadine; Antiviral Agents; Disease Progression; Dopamine Agents; Drug Administration Schedu | 2001 |
Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; F | 1978 |
Treatment of cocaine dependence in methadone maintenance clients: a pilot study comparing the efficacy of desipramine and amantadine.
Topics: Adolescent; Adult; Amantadine; Baltimore; Cocaine; Desipramine; Female; Follow-Up Studies; Humans; M | 1992 |
Amantadine may facilitate detoxification of cocaine addicts.
Topics: Adult; Amantadine; Cocaine; Day Care, Medical; Double-Blind Method; Follow-Up Studies; Humans; Male; | 1992 |
Bromocriptine and amantadine in cocaine detoxification.
Topics: Adult; Amantadine; Brain; Bromocriptine; Clinical Trials as Topic; Cocaine; Humans; Male; Random All | 1989 |
A pilot trial of amantadine for ambulatory withdrawal for cocaine dependence.
Topics: Adult; Amantadine; Bromocriptine; Clinical Trials as Topic; Cocaine; Double-Blind Method; Humans; Pa | 1988 |
Double-blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence.
Topics: Adolescent; Adult; Amantadine; Ambulatory Care; Bromocriptine; Clinical Trials as Topic; Cocaine; Do | 1987 |
The effect of adding amantadine to optimum L-dopa dosage in Parkinson's syndrome.
Topics: Aged; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Synergism; Female; Humans; | 1973 |
24 other studies available for amantadine and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Amantadine withdrawal in a patient with spinocerebellar ataxia.
Topics: Amantadine; Deglutition Disorders; Humans; Male; Parkinson Disease; Spinocerebellar Ataxias; Substan | 2023 |
The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status.
Topics: Aged; Amantadine; Catatonia; Delirium; Dopamine Agents; Electroconvulsive Therapy; Humans; Male; Mid | 2017 |
Comparative Assessment of the Effectiveness of Noncompetitive NMDA Receptor Antagonists Amantadine and Hemantane in Morphine Withdrawal Syndrome Model.
Topics: Adamantane; Amantadine; Animals; Gene Expression; Hyperalgesia; Injections, Intraperitoneal; Male; M | 2019 |
Case files of the program in medical toxicology at brown university: amantadine withdrawal and the neuroleptic malignant syndrome.
Topics: Amantadine; Antipsychotic Agents; Diagnosis, Differential; Drug Therapy, Combination; Female; Fluid | 2009 |
Parkinsonism-hyperpyrexia syndrome due to abrupt withdrawal of amantadine.
Topics: Amantadine; Humans; Male; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease, Secondary; | 2011 |
A case of temporary finger tremors due to amantadine withdrawal.
Topics: Aged, 80 and over; Amantadine; Antiparkinson Agents; Female; Fingers; Humans; Substance Withdrawal S | 2008 |
Noncatecholaminergic treatments of tardive dyskinesia.
Topics: Amantadine; Anti-Anxiety Agents; Benzodiazepines; Cyproheptadine; D-Ala(2),MePhe(4),Met(0)-ol-enkeph | 1982 |
Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine.
Topics: Amantadine; Antipsychotic Agents; Fever; Heat Exhaustion; Humans; Male; Middle Aged; Substance Withd | 1984 |
Withdrawal-induced neuroleptic malignant syndrome.
Topics: Aged; Amantadine; Humans; Male; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdra | 1994 |
Continuous or intermittent cocaine administration: effects of amantadine treatment during withdrawal.
Topics: Amantadine; Animals; Behavior, Animal; Cocaine; Drug Tolerance; Male; Rats; Rats, Sprague-Dawley; Su | 1994 |
Amantadine withdrawal and neuroleptic malignant syndrome.
Topics: Amantadine; Bromocriptine; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Subs | 1993 |
Acute delirium after withdrawal of amantadine in Parkinson's disease.
Topics: Acute Disease; Age of Onset; Aged; Amantadine; Delirium; Female; Humans; Male; Parkinson Disease; Su | 1998 |
Acute delirium after withdrawal of amantadine in Parkinson's disease.
Topics: Amantadine; Delirium; Humans; Parkinson Disease; Substance Withdrawal Syndrome | 1999 |
Neuroleptic malignant syndrome following withdrawal of amantadine in a patient with influenza A encephalopathy.
Topics: Adolescent; Amantadine; Antiviral Agents; Brain Diseases; Dopamine Antagonists; Humans; Influenza, H | 2001 |
Precipitation of abstinence-like syndrome in morphine-dependent mice by pargyline.
Topics: Amantadine; Amphetamine; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Drug Synergism | 1976 |
Amantadine in senile dementia: electroencephalographic and clinical effects.
Topics: Administration, Oral; Aged; Amantadine; Anxiety; Dementia; Depression; Electroencephalography; Femal | 1979 |
The influence of agonists and antagonists of dopaminergic system on the formation of audiogenic seizures in rats during the ethanol abstinence period.
Topics: Amantadine; Animals; Bromocriptine; Dopamine Agents; Dopamine Antagonists; Ethanol; Haloperidol; Mal | 1990 |
Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine.
Topics: Aged; Amantadine; Dementia; Drug Therapy, Combination; Haloperidol; Humans; Male; Neuroleptic Malign | 1989 |
Cocaine withdrawal. An effective three-drug regimen.
Topics: Amantadine; Cocaine; Humans; Lorazepam; Substance Withdrawal Syndrome; Substance-Related Disorders; | 1989 |
Stepwise detoxification from cocaine. A promising regimen.
Topics: Adolescent; Adult; Amantadine; Bromocriptine; Cocaine; Desipramine; Drug Therapy, Combination; Femal | 1988 |
A case of neuroleptic malignant syndrome treated with diazepam.
Topics: Aged; Amantadine; Diazepam; Humans; Male; Neuroleptic Malignant Syndrome; Substance Withdrawal Syndr | 1987 |
Neuroleptic malignant syndrome and amantadine withdrawal.
Topics: Acute Disease; Amantadine; Basal Ganglia Diseases; Female; Humans; Middle Aged; Neuroleptic Malignan | 1985 |
Dopamine agonists and neuroleptic malignant syndrome.
Topics: Alzheimer Disease; Amantadine; Basal Ganglia Diseases; Bromocriptine; Dantrolene; Humans; Male; Midd | 1985 |
[Neuroleptic malignant syndrome. A case associated with amantadine withdrawal].
Topics: Amantadine; Female; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Substance Withdrawal Syndro | 1985 |